Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunopharmacol Immunotoxicol. 2012 Oct;34(5):721-6. doi: 10.3109/08923973.2011.589453. Epub 2012 Feb 11.

Siglec-8 and Siglec-F, the new therapeutic targets in asthma.

Author information

  • 1Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

The recruitment of eosinophils from the circulation into the airway is a prominent feature of allergic asthma. Persistent inflammatory responses may arise from inefficient mechanisms for resolution of inflammation, including delayed apoptosis. Several studies suggest that eosinophil apoptosis is delayed in asthma. Sialic acid-binding immunoglobulin-like lectins are characterized by their sequence similarities and abilities to bind sialic acids in glycoproteins and glycolipids. Siglec-8 is uniquely expressed on eosinophils, mast cells, and basophils. Engagement of Siglec-8 on blood eosinophils results in caspase- and mitochondria-dependent apoptosis. Eosinophil apoptosis is an important therapeutic target for the development of novel anti-asthma treatments that specifically target the eosinophil.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk